Add wos sample results library

02-data/intermediate/wos_sample/25531df44e10c9c30e5be3673d585e8e-calderon-auaricio-a/info.yaml

@@ -0,0 +1,104 @@
+abstract: 'Background: Anti-cancer cytotoxic treatments like platinum-derived
+
+  compounds often show low therapeutic efficacy, high-risk side effects
+
+  and resistance. Hence, targeted treatments designed to attack only
+
+  tumour cells avoiding these harmful side effects are highly needed in
+
+  clinical practice. Due to this, precision oncology has arisen as an
+
+  approach to specifically target alterations present only in cancer
+
+  cells, minimising side effects for patients. It involves the use of
+
+  molecular biomarkers present in each kind of tumour for diagnosis,
+
+  prognosis and treatment. Since these biomarkers are specific for each
+
+  cancer type, physicians use them to stratify, diagnose or take the best
+
+  therapeutic options for each patient depending on the features of the
+
+  specific tumour.
+
+  Aim: This review aims to describe the current situation, limitations,
+
+  advantages and perspectives about precision oncology in Latin America.
+
+  Main body: For many years, many biomarkers have been used in a clinical
+
+  setting in developed countries. However, in Latin American countries,
+
+  their broad application has not been affordable partially due to
+
+  financial and technical limitations associated with precarious health
+
+  systems and poor access of low-income populations to quality health
+
+  care. Furthermore, the genetic mixture in Latin American populations
+
+  could generate differences in treatment responses from one population to
+
+  another (pharmacoethnicity) and this should be evaluated before
+
+  establishing precision therapy in particular populations. Some research
+
+  groups in the region have done a lot of work in this field and these
+
+  data should be taken as a starting point to establish networks oriented
+
+  to finding clinically useful cancer biomarkers in Latin American
+
+  populations.
+
+  Conclusion: Latin America must create policies allowing excluded
+
+  populations to gain access to health systems and next generation
+
+  anti-cancer drugs, i.e. high-cost targeted therapies to improve
+
+  survival. Also, cancer clinical research must be oriented to establish
+
+  cancer biomarkers adapted to specific populations with different
+
+  ethnicity, allowing the improvement of patient outcomes.'
+affiliation: 'Orue, A (Corresponding Author), IVIC, Ctr Microbiol, Tumor Cell Biol
+  Lab, Caracas 1020A, Venezuela.
+
+  Calderon-Auaricio, Ali; Orue, Andrea, IVIC, Ctr Microbiol, Tumor Cell Biol Lab,
+  Caracas 1020A, Venezuela.'
+article-number: '920'
+author: Calderon-Auaricio, Ali and Orue, Andrea
+author-email: andreaorue@gmail.com
+author_list:
+- family: Calderon-Auaricio
+  given: Ali
+- family: Orue
+  given: Andrea
+da: '2023-09-28'
+doi: 10.3332/ecancer.2019.920
+files: []
+issn: 1754-6605
+journal: ECANCERMEDICALSCIENCE
+keywords: 'precision oncology; biomarkers; cancer; targeted therapy; access to
+
+  health care; Latin America'
+keywords-plus: 'CELL LUNG-CANCER; ANDROGEN RECEPTOR; PERSONALIZED MEDICINE; OPEN-LABEL;
+
+  METHYLATION; EPIGENOMICS; MUTATIONS; THERAPY; DRUGS; EGFR'
+language: English
+month: APR 3
+number-of-cited-references: '78'
+orcid-numbers: Calderon-Aparicio, Ali/0000-0003-0656-1434
+papis_id: fc9d7da5e3f031b464597b9888d132ba
+ref: Calderonauaricio2019precisiononcology
+times-cited: '7'
+title: 'Precision oncology in Latin America: current situation, challenges and perspectives'
+type: Article
+unique-id: WOS:000464006000001
+usage-count-last-180-days: '0'
+usage-count-since-2013: '2'
+volume: '13'
+web-of-science-categories: Oncology
+year: '2019'